Prevalence of NAFLD, MAFLD, and MASLD: NHANES 1999-2018 - 13/07/24
Doi : 10.1016/j.diabet.2024.101562
Jie Pan a, Feilong Wu a, Mingtao Chen a, Jinsen He a, b, Yingying Gu a, Lei Pei a, Xuye Lai a, Zhenfeng Zhang c, 1, 2 
, Lili Yang a, 2, ⁎
, Lili Yang a, 2, ⁎ a Guangdong Provincial Key Laboratory of Food, Nutrition and Health, Department of Nutrition, School of Public Health, Sun Yat-sen University, Guangzhou, China
b Chancheng District Center for Disease Control and Prevention, Foshan, China
c Department of Radiology, Translational Medicine Center, Guangzhou Key Laboratory for Research and Development of Nano-Biomedical Technology for Diagnosis and Therapy & Guangdong Provincial Education Department Key Laboratory of Nano-Immunoregulation Tumor Microenvironment, Central Laboratory, the Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
⁎Corresponding author at: Department of Nutrition, School of Public Health, Sun Yat-sen University, No. 74, Zhongshan Road 2, Yuexiu District, Guangzhou, Guangdong 510080 China.Department of NutritionSchool of Public Health, Sun Yat-sen UniversityNo. 74, Zhongshan Road 2, Yuexiu DistrictGuangzhouGuangdong510080China
Keywords : MAFLD, MASLD, NAFLD, Prevalence
Le texte complet de cet article est disponible en PDF.
Plan
© 2024
Elsevier Masson SAS. Tous droits réservés.
Vol 50 - N° 6
Article 101562- novembre 2024 Retour au numéro
Article précédent
- Prevalence of NAFLD, MAFLD, and MASLD: NHANES 1999-2018
- Jie Pan, Feilong Wu, Mingtao Chen, Jinsen He, Yingying Gu, Lei Pei, Xuye Lai, Zhenfeng Zhang, Lili Yang
- Is plasma 16:0 ceramide a marker of cardiovascular risk?
- Christian Saleh
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?